Want to see OKUR full AI Analyst Report?
OKUR Stock Chart & Stats
$4.12
-$0.07(-1.70%)
At close: 4:00 PM EDT
$4.12
-$0.07(-1.70%)
Day’s Range― - ―
52-Week Range$1.91 - $5.38
Previous Close$4.05
Volume82.67K
Average Volume (3M)86.56K
Market Cap
$154.31M
Enterprise Value-$135.08
Total Cash (Recent Filing)$192.11M
Total Debt (Recent Filing)$409.00K
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Nov 05, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.33
Shares Outstanding40,395,480
10 Day Avg. Volume131,167
30 Day Avg. Volume86,556
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.70
Price to Sales (P/S)0.00
P/FCF Ratio-0.76
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$22.33Price Target Upside442.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.36
Revenue Forecast (FY)$500.00K
Bulls Say, Bears Say
Bulls Say
Low Leverage And Sizable Asset BaseVery low reported debt and a materially larger equity and asset base provide financial flexibility for a development-stage biotech. A strong balance sheet supports continued R&D investment, reduces near-term refinancing pressure, and lengthens the runway versus peers reliant on high leverage.
Focused Next‑generation PI3Kα Program With IND TimelinesA clear strategic pivot to next‑gen PI3Kα pan‑mutant selective inhibitors with IND‑enabling progress and planned 2027 IND submissions signals focused R&D prioritization. Delivering INDs would transition the company to clinical milestones and potentially de‑risk the pipeline over the medium term.
Equity Incentive Plan Supports Talent And ExecutionAn expanded, evergreen equity incentive plan gives management flexibility to attract and retain scientific and product development talent, aligning compensation with long‑term goals. For an R&D‑heavy biotech, this supports sustained execution capacity and program continuity.
Bears Say
No Product Revenue; Widening Net LossesThe company remains pre‑revenue with widening annual losses, meaning value is entirely contingent on future clinical success. Continued negative earnings erode equity over time and require sustained external financing to fund development, heightening execution and dilution risk if trials falter.
Elevated Cash Burn And Negative Free Cash FlowPersistently negative operating and free cash flow at elevated levels indicates ongoing reliance on external funding. Even with a healthy balance sheet today, sustained burn without near‑term revenue or milestone receipts increases refinancing frequency and the risk of dilution over the medium term.
Equity Plan Evergreen Raises Dilution RiskWhile enabling retention, the removal of a fixed cap and an evergreen annual increase amplifies potential share issuance over time. For a cash‑burning biotech, routine equity issuances become likelier to fund operations, which may materially dilute existing holders and pressure per‑share economics.
OnKure Therapeutics News
OKUR FAQ
What was OnKure Therapeutics’s price range in the past 12 months?
OnKure Therapeutics lowest stock price was $1.91 and its highest was $5.38 in the past 12 months.
What is OnKure Therapeutics’s market cap?
OnKure Therapeutics’s market cap is $154.31M.
When is OnKure Therapeutics’s upcoming earnings report date?
OnKure Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 92 days.
How were OnKure Therapeutics’s earnings last quarter?
OnKure Therapeutics released its earnings results on Aug 04, 2026. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.535 by $0.225.
Is OnKure Therapeutics overvalued?
According to Wall Street analysts OnKure Therapeutics’s price is currently Undervalued.
Does OnKure Therapeutics pay dividends?
OnKure Therapeutics does not currently pay dividends.
What is OnKure Therapeutics’s EPS estimate?
OnKure Therapeutics’s EPS estimate is -0.51.
How many shares outstanding does OnKure Therapeutics have?
OnKure Therapeutics has 40,395,480 shares outstanding.
What happened to OnKure Therapeutics’s price movement after its last earnings report?
OnKure Therapeutics reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.535. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of OnKure Therapeutics?
Currently, no hedge funds are holding shares in OKUR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OnKure Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.33 (442.07% Upside)
$22.33 (442.07% Upside)
Blogger Sentiment
Bullish
OKUR Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.51%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
98.93%
Trailing 12-Months
Company Description
OnKure Therapeutics
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
OKUR Stock 12 Month Forecast
Average Price Target
$22.33
▲(442.07% Upside)
Technical Analysis
Ownership Overview
1.73% Insiders
1.69% Mutual Funds
63.84% Other Institutional Investors
26.41% Public Companies and
Individual Investors